# Multidimensional regulatory roles and therapeutic applications of SRSF7 in cancer

**Authors:** Yuan Li, Huimeng Gao, Xuanyu Zhang, Fuli Sun, Yan Guo, Xue Qiao

PMC · DOI: 10.1038/s41420-025-02937-4 · Cell Death Discovery · 2025-12-30

## TL;DR

This review explores the role of SRSF7 in cancer, highlighting its regulatory functions and potential as a therapeutic target.

## Contribution

The paper provides a comprehensive overview of SRSF7's molecular mechanisms in tumorigenesis and its therapeutic potential.

## Key findings

- SRSF7 is involved in epigenetic reprogramming and regulation of the cell cycle in various cancers.
- It influences non-coding RNA, RNA methylation, and glucose metabolism in tumor development.
- SRSF7 contributes to immune evasion and tumor resistance through alternative splicing.

## Abstract

Malignant tumors, as one of the leading causes of mortality, pose great threats to global public health. Serine/Arginine-rich Splicing Factor 7 (SRSF7), a core splicing regulatory protein of the SRSF family, plays a crucial role in maintaining RNA stability, facilitating alternative splicing, and assisting RNA nuclear export. It also exhibits significantly aberrant expression among various cancers, including lung, colorectal, liver, and oral cancer. This review examines the molecular mechanisms of SRSF7 in tumorigenesis, with a focus on its role in the epigenetic reprogramming of related tumors. Specifically, it explores the abnormal regulation of the cell cycle, the regulation of non-coding RNA, the control of RNA methylation, and the reprogramming of glucose metabolism. Additionally, this review examines the role of SRSF7 in the tumor immune microenvironment through alternative splicing and immune evasion through the immune checkpoint PD-1. It also highlights the role of SRSF family members in tumor resistance, illustrating how alternative splicing contributes to tumor chemoresistance. Although SRSF7 shows significant promise in tumor intervention therapies, more experimental and clinical studies are still needed to evaluate its clinical application. This review enhances our understanding of the molecular landscape of SRSF7 in tumorigenesis with great potential to become a key node in tumor-targeted therapy and companion diagnostics, driving translational potential from mechanisms to clinical applications.

## Linked entities

- **Genes:** SRSF7 (serine and arginine rich splicing factor 7) [NCBI Gene 6432], Gm6687 (predicted gene 6687) [NCBI Gene 626575]
- **Proteins:** PDCD1 (programmed cell death 1)
- **Diseases:** lung cancer (MONDO:0005138), colorectal cancer (MONDO:0005575), liver cancer (MONDO:0002691), oral cancer (MONDO:0023644)

## Full-text entities

- **Genes:** SRSF7 (serine and arginine rich splicing factor 7) [NCBI Gene 6432] {aka 9G8, AAG3, SFRS7}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}
- **Diseases:** tumorigenesis (MESH:D063646), lung, colorectal, liver, and oral cancer (MESH:D015179), Malignant tumors (MESH:D009369)
- **Chemicals:** glucose (MESH:D005947)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12847704/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12847704/full.md

---
Source: https://tomesphere.com/paper/PMC12847704